Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Sep 1;26(9):3347-3352.
doi: 10.31557/APJCP.2025.26.9.3347.

mTOR Levels and Metastasis in Luminal Breast Cancer: Implications for Prognosis and Treatment

Maryam Mayidah Hasan Nur  1 , Prihantono Prihantono  2   3   4 , Muhammad Ihwan Kusuma  1   3 , Indra Indra  2 , Salman Ardi Syamsu  2   4 , Nilam Smaradhania  2   4 , John Pieter Jr  2 , Muhammad Faruk  1   4
Affiliations
Free article

mTOR Levels and Metastasis in Luminal Breast Cancer: Implications for Prognosis and Treatment

Maryam Mayidah Hasan Nur et al. Asian Pac J Cancer Prev. .
Free article

Abstract

Background: Breast cancer (BC) is the most common cancer in women, with metastasis being the leading cause of mortality. The PI3K/PTEN/Akt/mTORC1 signaling pathway plays a crucial role in cancer cell proliferation, angiogenesis, and invasion, with mammalian target of rapamycin (mTOR) serving as a key regulator. Activation of mTOR is associated with tumor growth and resistance to therapy in luminal and human epidermal growth factor receptor 2 positive (HER2-positive) BC subtypes. This study aims to explore the relationship between serum mTOR levels and metastasis in luminal, HER2-positive and HER2-negative BC subtypes to assess the potential of mTOR as a predictive biomarker and therapeutic target.

Methods: This preliminary cross-sectional study included BC patients with luminal HER2-positive or HER2-negative subtypes. Serum mTOR levels were measured using a Human ELISA kit. The optimal cut-off point for mTOR was determined using a Receiver Operating Characteristic (ROC) curve analysis. Statistical associations between mTOR levels and metastasis were performed using the Chi-square or Fisher's exact test, and the prevalence ratio (PR) with a 95% confidence interval was calculated.

Results: The ROC curve demonstrated an AUC of 0.996, with an optimal cut-off point for serum mTOR levels at 13.32 ng/mL, showing 100% sensitivity and 96.4% specificity for predicting metastasis. The mean mTOR level was 58.39±250.91 ng/mL, with 50% exhibiting elevated levels (≥13.32 ng/mL). Notably, mTOR levels were significantly higher in HER2-positive cases (113.59±381.87 ng/mL) compared to HER2-negative cases (17.45±14.83 ng/mL; p=0.040). Elevated mTOR levels were significantly associated with metastasis (p<0.001), with a PR of 0.037 (95% CI: 0.005-0.253).

Conclusions: Increased serum mTOR levels (≥13.32 ng/mL) are significantly linked to the presence of metastasis, particularly in HER2-positive BC. These findings suggest serum mTOR as a promising biomarker for metastasis risk and a potential therapeutic target in luminal BC.

Keywords: Biomarker; HER2; Metastasis; breast cancer; mTOR.

PubMed Disclaimer